• TGOD’s ability to secure significant capital reflects its establishment in industry and strong governance foundation
• The financing plan involved several components, including a sale-leaseback of Ancaster Energy Centre, a $40 million construction mortgage loan with an investment fund, and a $30 million convertible note.
• Company plans for utilization of capital include completing construction of its various facilities and achieving national product distribution

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium certified organic cannabis, recently signed agreements for increased funding amounting to up to $103 million. The company’s ability to secure capital at a time when cannabis companies are weathering the winds of a somewhat tempestuous market indicates investors’ faith in TGOD’s sound business practices, significant assets, and strong governance policies. TGOD is uniquely positioned in the industry as one of the only certified-organic cannabis companies, which when coupled with its recent funding acquisition shows its potential for strong growth in the cannabis sector.

The company’s diverse financing package consists of three pieces (http://ibn.fm/pxuqk), which include “a definitive agreement for a sale-leaseback of the Ancaster Energy Centre, a construction mortgage loan term sheet, and a convertible equity note term sheet.” The agreement for the Ancaster Energy Centre is non-dilutive, denotes proceeds of $23 million, and carries a 10-year term, after which TGOD is able to repurchase the center for $1.

A term sheet with an investment fund for a $40 million construction mortgage loan has also been signed, secured on the facilities at Ancaster and Valleyfield. With this term, $15 million will be payable on closing, with an additional $25 million advance available to TGOD once certain operational milestones are achieved later in 2020. The last segment of its financing involves TGOD’s entrance into a term sheet with an investment fund for a $30 million note with a 5% coupon, which is convertible into common shares of TGOD. These terms indicate that TGOD would receive $10 million upon closing with $20 million immediately placed into escrow to be released as the note is converted into common shares. Closing of the two non-binding term sheets is subject to various conditions, including entering into legally binding documentation, satisfactory due diligence and the receipt of required regulatory approvals. The company expects to close these transactions by the end of Q4, 2019, but there can be no assurance that the transactions close on that time frame or at all.

“Our ability to raise capital, despite recent headwinds affecting the entire sector, is a clear show of confidence from our financial partners,” TGOD CEO Brian Athaide stated in a news release. “It is reflective of the value of our significant assets, the trust investors are putting into TGOD’s strong corporate governance, transparency and accountability, and the opportunity for the company’s unique positioning to quickly capture and grow the organic segment.”

The Green Organic Dutchman, one of the few certified-organic licensed producers in Canada, has garnered industry attention because of its ability to cultivate premium product at competitive costs, due in large part to its industry partnerships, passion for product excellence, and sound governance principles. The company has accrued a significant following among cannabis enthusiasts and was recently described as one of the best licensed Canadian cannabis producers (http://ibn.fm/yENYp).

TGOD intends to use its increased capital from the financings to continue executing its plan for “rapid yet disciplined expansion,” focusing concretely on near-term profitability. In this vein, raised capital will be used to accomplish the following:

• Complete construction of the processing facility at Ancaster
• Complete construction of six zones in the Valleyfield hybrid greenhouse and enclose the balance of the facility with the ability to quickly expand production as the market develops.
• Provide adequate cash for working capital needs to bridge until the company anticipates generating positive operational cash flow
• Achieve national distribution of TGOD products in early 2020

The company continues to work toward its mission of nurturing a community focused on a sustainable way of life. With significant funding to power its multifaceted growth strategy, TGOD is well-positioned for continued success in the organic-cannabis sector.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Uber Technologies pioneered the open-access peer-to-peer ride-sharing model a decade ago, and is now operating in 67 countries with investment in multinational services continuing to grow
• Increasing concerns about criminal incidents and other problem behaviors has led the company to enhance its responsiveness to users’ safety, in regard to both drivers’ and passengers’ well-being
• The newest feature to launch will be an audio recording that can be enabled by either a driver or a passenger as an evidentiary tool
• The feature will test launch in Mexico and Brazil in December, with expectations of introducing it in the United States at a future point once state-by-state privacy laws are adequately addressed

Global peer transportation pioneer Uber Technologies Inc. (NYSE: UBER) is preparing to roll out an audio recording feature that will further enhance its safety measures in an attempt to provide peace of mind to the service’s drivers and passengers.

The feature will allow passengers and drivers to activate inalterable, encrypted audio recordings that users can ask the feature to submit to Uber’s customer support team if there is a need to report a safety issue, according to media reports confirmed by the company (http://ibn.fm/lB2lK). The recording will serve as a tool to help users “prove” the nature of a complaint if necessary.

Uber will store the recordings in case the user decides to submit a report after some delay following an incident, according to the company.

Uber has been increasing its responsiveness to safety concerns during recent months following a number of troubling situations reported to the company that have also gained media attention, including incidents in which alleged criminals have falsely presented themselves as Uber drivers in a bid to harm riders using the service. The company launched its Campus Safety Initiative to help students learn how to avoid fake ride share drivers (http://ibn.fm/bZiqK), followed by a new RideCheck feature that uses smartphones’ location sensors to analyze the movements of Uber’s vehicles (http://ibn.fm/KQI3W) and an in-app panic button for contacting 911.

The newest safety feature will begin testing in December in Mexico and Brazil, with plans to introduce it to the United States at an as-yet undetermined time afterward.

“Laws in the United States around consent to being recorded can vary from state to state, but we hope to be able to make this available nationally,” an email written by an Uber executive and subsequently published by The Washington Post states (http://ibn.fm/l2ajx).

Many states’ privacy laws require that all persons who may appear in an audio recording be notified and consent to being recorded, while some states only require that one person – ostensibly the one making the recording — be aware of the recording. Uber’s initial approach is to issue a blanket statement to the service’s users to notify them that they may be subject to an audio recording.

“We have taken a position that whenever you are in an Uber, the feeling that we want both parties to have is ‘the lights are on,’” Uber safety products director Sachin Kansal told The Post. “That leads to safer interaction on the platform.”

There is no notification sent to the driver or rider when the recording begins, part of an effort to avoid potentially escalating an already worrisome situation. Drivers can set the feature to automatically record all transports.

Mexico and Brazil, where the feature’s rollout will occur, represent Latin America’s two largest markets. Uber was operating in 67 countries as of its November 5 quarterly filing with the U.S. Securities and Exchange Commission (http://ibn.fm/MsXEf), covering the period through the end of September. The lion’s share of the company’s revenues come from operations in the United States, but the company continues to make significant investments to expand its international operations and compete with ride share services that are local to foreign markets.

For more information, visit the company’s website at www.Uber.com

• Revenues for the nine months ended September 30, 2019 also increased 293% to $161,720
• Company is selling SofPulse(R), its noninvasive Electroceutical(R) therapeutic device, in 7 hospitals, 11 surgery centers and 14 other medical facilities
• The device is currently under evaluation in 112 other healthcare facilities and Endonovo expects to become a premier supplier to hospitals nationwide for post-operative pain management

Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc. (OTCQB: ENDV) reported its financial results for the third quarter of 2019 via a press release issued on November 19, 2019 (http://ibn.fm/OfcoV). According to the announcement, Endonovo’s revenues increased by 153% to $54,039 in the third quarter of 2019, compared to $21,306 in the third quarter of 2018. Revenues for the nine months that ended on September 30, 2019 increased 293% to $161,720, as compared to $41,132 for the same period last year.

While the results fell short of initial projections, the company’s achievements in the first nine months of the year have been nonetheless significant, especially in what regards the national rollout of its flagship product, SofPulse(R) Electroceutical(TM) Therapy. A bioelectronics pain management device, Endonovo’s proprietary SofPulse(R) uses electromagnetic waves to speed up recovery by reducing inflammation. The device can treat cardiovascular diseases, inflammatory conditions, and central nervous system disorders such as traumatic brain injury acute concussions, post-concussion syndrome, and multiple sclerosis. The device also facilitates surgical wound recovery.

According to the company press release, SofPulse(R) is currently being used in seven hospitals, 11 surgery centers and 14 other medical facilities, and is being evaluated in other 92 hospitals and 20 additional medical centers. “The national rollout has been successful, however, hospitals testing and evaluation periods have been longer than initially expected. We respect the process, the policies and procedures some hospitals have before accepting a product into their medical facility and as part of their post-operative pain management protocols,” Endonovo Therapeutics CEO Alan Collier said.

The Electroceutical(R) Therapy device has prospects to reduce the need and intake of prescription drugs over the long term. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure in patients using SofPulse(R), according to company data. Use of the device leads to a 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication, and 50% less inflammation. SofPulse (R) works by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for recovery to occur.

The company currently has 113 trained sales representatives and masmter principals deployed across 50 states, and its main focus is to expand operations and get its Electroceutical(R) Therapy in use at as many healthcare facilities as possible. “We continue to expand our client base and have seen significant traction in building Endonovo into a premier supplier to hospitals nationwide for post-operative pain,” Collier said. Plans to conduct studies and trials for additional medical indications such as myocardial infarction, chronic kidney disease, post-concussive syndrome and others have been shelved for the time being until the company becomes profitable.

According to Collier, the company is making bold decisions to accelerate operations and take full advantage of the multiple opportunities presented by the fast-changing post-op pain management market. “The opioid epidemic has been a global catastrophe and we remain committed to being at the forefront of replacing opioids in a natural and safe manner. We are targeting areas to drive improved marketing performance and are confident we are pursuing the necessary changes to deliver superior shareholder value,” Collier concluded.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Pharmaceutical services business Trxade Group recently reported its third quarter financials, showing a new record for revenues amid continued growth in the company’s business-to-consumer operation and services to independent pharmacies
• The company’s revenue growth amounted to a 173 percent year-over-year increase for the quarter
• Trxade Group’s quarterly report also showcased growing gross profits (with a decreasing gross margin), shareholder equity and operating income
• The company offers a web-based platform that maintains market intelligence on over 20,000 medications and provides pricing and supply alerts to members to help them secure the best possible prices
• Subscription in Trxade Group’s platform continued to grow during the quarter, adding 431 independent pharmacies, which amounts to a nine percent increase over the prior quarter and a 54 percent increase over the prior year

Third quarter financial results reported recently show Trxade Group Inc. (OTCQB: TRXD) is continuing to maintain a profitable integrated pharmacy services operation while working to redefine the health care industry for the betterment of small independent pharmacists nationwide.

Trxade Group’s acquisition of Community Specialty Pharmacy, LLC last year continues to drive the company’s revenue benchmarks, delivering sales that lifted the company to record revenues of $2.3 million for the quarter and nine-month year-to-date revenues of $5.7 million, which amount to increases of 173 percent and 126 percent over previous year figures, respectively, according to the company’s news release (http://ibn.fm/52imL).

Gross profits for the third quarter rose in tandem with the revenues, increasing from $845,126 last year to $1.3 million this year. For the year, through the end of September, gross profit was $3.6 million with a gross margin of 63 percent, improving from $2.5 million and 99.5 percent a year earlier.

According to the company, the improvement reflects “a sales mix with greater revenue from Specialty pharmaceutical sales, which carries a higher cost of sales, reflecting the lower margin, than the Company’s other revenue sources.”

In the process, shareholder equity increased to $3.9 million and the company’s debt was reduced, showing the strength of Trxade’s financial controls and operational plan. Operating income also increased by 94 percent, marking the seventh quarter in a row that the company has had positive operating income.

“During the third quarter of 2019, we made excellent progress in our core proprietary B2B trading platform www.Trxade.com, which enables independent pharmacies to purchase drugs at discount prices compared to their primaries, enabling us to experience top and bottom line growth,” Chairman and CEO Suren Ajjarapu stated in a news release. “Additionally, we are investing in core infrastructure for our B-to-C (Community Specialty Pharmacy) business in our wholesale, e-commerce and delivery capabilities as increasing pharmaceutical prices drive independent pharmacies, payors and consumers to be more aggressive in sourcing medication.”

The company is currently preparing to begin the process of upgrading to regular Nasdaq listing.

The Community Specialty Pharmacy (or ComspRX) business’s online extension obtained certification as a legitimate and reputable pharmaceutical operation by LegitScript, an independent third-party compliance organization utilized by Google, Facebook, Visa and Mastercard to vet drug advertisers on their platforms. ComspRX holds 15 state licenses, having been certified by non-profit organization Accreditation Commission for Health Care (ACHC).

The Florida-based Trxade Group pioneered the supplier-to-pharmacy trading platform. The platform helps independent pharmacies avoid the difficulties that come with losing reimbursement costs and helps them identify the most competitive prices available for preferred prescription drugs. Pharmacy subscriptions to the platform have grown steadily, adding 431 new independent pharmacies during the third quarter – a nine percent increase from the prior quarter and a 54 percent increase from a year earlier.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Willow’s plan to provide biosynthetic cannabinoid has potential to disrupt the cannabis-industry supply chain
• Biosynthetically derived cannabinoids offer unique advantages related to reliability, scalability, quality and cost
• Key collaboration allows company to capitalize on enormous market opportunity

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF), an emerging biotechnology company focused on the biosynthetic production of cannabinoids, believes that the cannabis industry presents an exciting opportunity for the well-positioned company. As the market anticipates the legalization of cannabis-derivative products in Canada, and the CBD legal landscape continues to change rapidly in the United States and around the world, cannabinoids are appearing as a key ingredient in a broad range of products, from health and wellness and pet care options to beverages and edibles. Willow’s ability to provide biosynthetic cannabinoids to this exploding market has the potential to disrupt the traditional cannabis industry supply chain.

Biosynthetically derived cannabinoids offer unique advantages related to reliability, scalability, quality, and cost. As an expert in the field of synthetic biology, Willow is focusing on developing pure, pharmaceutical-grade product that consistently provides these benefits for its customers. Willow’s processes offer many advantages over extraction from plants, including the possibility of improving the performance of some cannabinoids over their naturally derived versions.

As part of the company’s savvy strategy to become a leader in the pure-cannabinoid manufacturing space, Willow entered into a joint development agreement with Noramco, the number one supplier of controlled substances in the United States, earlier this year (http://ibn.fm/HEemD). This collaboration provides a symbiotic way for both companies to capitalize on an enormous market opportunity.

Noramco will benefit from Willow’s expertise in developing active pharmaceutical ingredients in yeast while Willow will benefit from Noramco’s manufacturing and distribution channels. In addition, thanks to Noramco’s extensive experience in dealing with various regulatory bodies, WLLW could save a significant amount of time and resources associated with regulatory submissions. Finally, Willow can leverage Noramco’s supply-chain expertise in selling synthetic CBD. Noramco currently supplies products to over 30 countries and is a supplier of chemically synthesized cannabinoids to pharmaceutical companies.

The market outlook for biosynthetic cannabinoid products is extremely promising. Cowen estimates that by 2025, the United States CBD market could reach $16 billion (http://ibn.fm/DgxEe). Additionally, Ackrell Capital estimates that the pharmaceutical market for cannabinoids will reach $50 billion by 2029 (http://ibn.fm/gv9Vt). With the goal of being one of the first companies providing biosynthetic alternatives in this space, Willow sees a tremendous opportunity to grab a sizeable market share in a fast-growing global market.

This is especially true on the pharma front where the list of trials and indications continues to grow rapidly. Approximately 40 CBD and other cannabinoid-based treatment options are currently in clinical trials for indications such as post-traumatic stress disorder, epilepsy, Parkinson’s disease, chronic pain, schizophrenia and others (http://ibn.fm/fiLac). Applications for pharmaceutical-grade cannabinoids is expected to continue to expand.

If only a handful of those clinical trials become successful, WLLW expects to see market size for cannabinoids increase substantially, providing Willow will have a significant opportunity to supply biosynthetically derived cannabinoids to various pharmaceutical companies for use in pre-clinical and eventually clinical trials.

Willow ultimately intends to biosynthetically produce a variety of cannabinoids using biosynthesis, but its first target molecule will be CBD. The company has a fully integrated leadership team based out of Canada and the United States to handle all stages of the upstream cannabinoid development cycle. Additionally, by having two labs in Canada, where cannabis is Federally legal, Willow is able to access and work with the cannabis plant to allow its team to make significant discoveries outside of what is known today. This is a key advantage for the company. Willow is fully funded to achieve commercialization of CBD with its partner Noramco.

For more information, visit the company’s website at www.WillowBio.com

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW

• Wholly owned subsidiary Semcon IP Inc. resolves all claims and disputes by and between Semcon IP Inc. and AsusTek Computer Inc. relating to Semcon’s Power Management Portfolio
• Semcon’s licensing program has seen significant activity in 2019 with additional cases pending
• Trading on the OTCQB and with patent licensing revenues for the nine-months ended September 30, 2019, of approximately $2 million, QPRC offers investors an exciting opportunity to participate in the IP monetization space

The Power Management/Bus Controller Portfolio, acquired by company Quest Patent Research Corp. (OTCQB: QPRC) from Intellectual Ventures in October 2015 and transferred to wholly owned subsidiary, Semcon IP Inc., consists of four United States patents that cover fundamental technology for adjusting the processor clock and voltage to save power based on the operating characteristics of the processor and one United States patent that relates to coordinating direct bus communications between subsystems in an assigned channel.

In May 2018, Semcon brought a patent infringement action in the United States District Court for the Eastern District of Texas against AsusTeK Computer Inc. for infringement of certain of the Power Management Portfolio, alleging that “Asus has infringed and is continuing to infringe the Patents-in-Suit by making, using, selling, offering to sell, and/or importing, and by actively inducing others to make, use, sell, offer to sell and/or importing, products that utilize SoCs and associated software that perform DCVS or DVFS for power management, including Qualcomm Snapdragon SoCs including at least the Snapdragon 800, 820 and 821 SoCs. Such Asus products include at least the Zenfone 3 Ultra, Zenfone 3 Deluxe, Zenfone AR, Zenpad 3 and Padfone X smartphones and tablets. Additionally, these Asus products include software that utilizes DCVS and/or DVFS for power management.” A copy of the complaint is available at  http://ibn.fm/eAq6o.

In July 2019, Asus moved for summary judgement of non-infringement, only to withdraw their motion in late August. A copy of the motion is available at http://ibn.fm/adlA2, and Semcon’s response is available at http://ibn.fm/mCY79. In September 2019, Asus moved for leave to serve amended initial disclosures and to produce discovery out of time. A copy of the motion is available at http://ibn.fm/cD2ME, and Semcon’s response is available at http://ibn.fm/HAfhC.

A Pretrial Conference was held on October 28, 2019, during which the court gave the parties instructions for jury selection, set trial for December 9th, heard oral arguments on the motion to leave, denied the motion and ordered the parties to return to mediation. The minutes from the pretrial conference are available at http://ibn.fm/p4uwd.

The Supplemental Mediators Report, filed with the court on November 18, 2019, states “a settlement has been reached as to all claims by and between Plaintiff Semcon IP, Inc. and Defendant AsusTek Computer Inc. This case is now settled.” A copy of the mediator’s report is available at http://ibn.fm/k97QB.

Semcon’s licensing program has seen substantial activity of late having recently resolved cases against Capri Holdings Limited (f/k/a/ Michael Kors Holdings Limited), Kyocera Corporation and Amazon.com, Inc. Semcon has additional cases pending against Louis Vuitton North America, Inc. (TXED-2-19-cv-00122); TCT Mobile International Limited et al (TXED-2-18-cv-00194); and Shenzhen OnePlus Science & Technology Co., Ltd. (TXED-2-18-cv-00196).

Revenues for the period ended September 30, 2019, which were approximately $2 million according to the Company’s most recent quarterly report (available at http://ibn.fm/qVQZ9). Annual revenues have grown from around $200,000 in 2015 to approximately $7 million in 2018. Quest trades on the OTCQB.

For more information, visit the company’s website at www.QPRC.com

NOTE TO INVESTORS: The latest news and updates relating to QPRC are available in the company’s newsroom at  http://ibn.fm/QPRC

• CIIX anticipates launch of hemp-infused wrinkle cream in China
• Through subsidiary CBD Biotech, CIIX will focus hemp and CBD products on the blooming Chinese market
• The company noted impressive sales, revenue growth for Q1 2020, greatly due to success of CBD Biotech

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang noted the enormous potential for cosmetics infused with industrial hemp in a RedChip Money Report interview. This sentiment was echoed in his letter to shareholders, where he noted that CBD-infused cosmetics will the company and its subsidiary, CBD Biotech, to a Chinese market of 1.4 billion people. CIIX plans to launch industrial hemp-infused wrinkle cream cosmetics to this market in the near future (http://ibn.fm/4G7xU).

In the interview, Wang outlined the company’s historic presence in China’s’s burgeoning CBD-industry. As the first company to enter the Chinese CBD products market, the move represents tremendous opportunity for CIIX’s CBD division, he said. Additionally, the company has been marketing its CBD products to Chinese-speaking American consumers since it entered the industry in 2017. Wang referenced the incredible market potential of the more than 3.5 million Chinese consumers in the United States, to which CIIX already markets gummies, CBD oil, and CBD-infused cosmetics (http://ibn.fm/EQcsr).

Looking forward, Wang described the company’s intent to diversify its revenue streams in FY2020, planning to focus on its core investor relations business as well as continuing to expand and market its industrial hemp-infused/CBD products in China and the United States. This strategy shows potential for greater revenues and profits, as “the buying power from the Chinese consumer will be huge,” he said.

“While cannabis use in China is illegal, cannabis-based oils including industrial hemp extract may be added to cosmetics, thus opening a potential market of nearly 1.4 billion people for the company,” Wang noted. “As we analyze the legality/trends in other Asian countries, we have an advantage with ‘feet on the ground’ in that part of the world.”

CIIX will also focus in 2020 on its core business of investor relations. It already owns a minority interest in a U.S.-based investment bank, Donald Capital, LLC and is in the process of establishing a “working cooperation” with a private equity firm in China. Wang said, “Both of these relationships are projected to be a source of recurring revenue for years to come.”

This continued emphasis on its CBD arm has led CIIX to impressive revenue reporting. CIIX reported in its 8K filing to the SEC sharply higher revenues for Q1 2020, the three months ended August 31, 2019. Sales jumped to $1,956,960, 174.7% higher than the $712,360 for the same quarter the prior year. Hemp and CBD product revenues drove that increase with a contribution of $948,751 for the 2020 quarter, a 569.2% rise from the $141,764 in Q1 2019 (http://ibn.fm/nArjp).

Additionally, CIIX’s core investor relations business generated $821,361 in Q1 2020, a 200% improvement over the $271,248 the same period the prior year. CIIX has refocused and grown its core business (http://ibn.fm/cltnt).

With an eye toward profitability, CIIX is streamlining its operations and maximizing current resources across the board. As it refocuses on its core investor relations business and diversifies and grows its industrial hemp/infused products in China and the U.S., Wang is optimistic. Wang said, “Although we still have work to do in this regard, with these objectives in mind, with a dedicated and experienced management team, and most importantly, the continued support of our loyal shareholders, we look forward to a healthy FY2020.”

CIIX offers its audience of Chinese-speaking investors real time market commentary, analysis and educational-related services in Chinese character language sets. When asked why investors should put their trust in CIIX, Wang said, “We have been around for 20 years. We put our roots into the United States of America, so I believe people can trust us. We are right here, right now, and local.” CIIX offers investors an inexpensive stock option poised on the brink of tremendous market opportunity in China’s growing CBD-infused cosmetic industry.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• An estimated 20% of wastewater is treated globally, with much lower percentage being recycled
• OriginClear addresses situation by providing water-treatment and conveyance products that are installed on site
• CEO has goal for company to be driving force to take water industry from $1 trillion to a $5 trillion market

In a world where an estimated 20% of wastewater globally is treated and a much lower percentage is recycled (http://ibn.fm/IGQZW), OriginClear Inc. (OTC: OCLND) may be key to the solution. A leading provider of water-treatment solutions, OriginClear is uniquely prepared to offer organizations of all types – hotels and resorts, real-estate housing developments, office buildings, military installations, schools, farms, food and beverage manufacturers, industrial warehouses, oil and gas producers, medical and pharmaceutical facilities and more – the tools and services to treat and recycle their own water.

In a recent Grit Daily article (http://ibn.fm/aHErZ), the author noted that OCLN CEO Riggs Eckelberry is “driving the disruption of a trillion-dollar industry that has fallen behind the times and is affecting the health of millions. That industry is Big Water.” Billion-dollar centralized water systems aren’t coping with demand, the article reported, and water quality is steadily getting worse. Eckelberry “has a goal for his company, OriginClear, to be the driving force to take the water industry from $1 trillion to a $5 trillion dollar market.”

The trillion-dollar number comes from a “Water Online” report, which states that “a water scarcity ‘perfect storm’ is approaching, and that makes it a good time to invest in water reuse technologies. Analysts at Bank of America Merrill Lynch Global Research said in a new report. ‘For investors, increased demand for water could generate potent investment opportunities. Water-related industries already represent a roughly $500 billion market,’ the report said, citing Sarbjit Nahal, an equity strategist at BofA Merrill Lynch Global Research. ‘We think it will double to $1 trillion by 2020,’ he said” (http://ibn.fm/xClqg).

Eckleberry explains how OriginClear believes that $1 trillion estimate can increase to $5 trillion by noting that, based on a UN World Water Development report (http://ibn.fm/KSml2), over 80% of all wastewater is discharged without treatment. “If only 20% of the water is treated,” Eckleberry noted in a recent CEO update (http://ibn.fm/YD1jD), “this one-trillion dollar industry should be a five-trillion dollar industry.”

OriginClear plans to build this industry by providing professional-grade, water-treatment and conveyance products that are installed onsite at commercial and industrial properties. The company is leading a new generation of water companies that are committed to serving businesses looking for compact, advanced technologies at the point of use, with modular systems that are shipped to the site and dropped in place.

The benefit of these systems is vast. Once installed, OriginClear water-treatment solutions boost a client’s real-estate asset value as a fundamental capital improvement, provide long-lasting water savings, create self-sufficiency by providing water ownership, offer control over water quality, increase productivity and reduce environmental, health and safety risks from pollution, contamination and corrosion.

OriginClear offers breakthrough water-treatment and conveyance products that effectively improve the quality of water by returning it to its original and clear condition. OCLN’s stated mission is to empower this global movement with products that enable water independence and help make clean water available for all. The company provide modular water-purification systems, storage systems, pump stations, wastewater systems and control systems.

For more information, visit the company’s website at www.OriginClear.com

NOTE TO INVESTORS: The latest news and updates relating to OCLN are available in the company’s newsroom at http://ibn.fm/OCLN

• InsuraGuest’s guest protection policy, extended to each guest at check-in, covers accident damages, loss, and accidental medical
• The InsuraGuest™ InsurTech platform can integrate with 70 hotel and vacation rental property management systems
• Number of vacation rental users expected to top 297 million worldwide in 2019

Service-as-a-software (SaaS) company InsuraGuest Inc. has entered the rapidly growing vacation rental market with its proprietary software platform offering specialized insurance coverage to all guests from check-in to check-out. InsuraGuest’s innovative InsurTech platform protects guests during their stay at vacation rental properties in an industry that is expected to host more than 297 million total vacation rental users worldwide in 2019 (http://ibn.fm/CMnjv).

Additionally, projected vacation-rental industry revenue for 2019 stands at $57.669 billion with a market growth rate of 6.9 percent. Statistics indicate that U.S. travel to overseas markets totaled 35.1 million, up by 7 percent, and that almost 25 percent of Americans report engaging with short-term rental platforms – a massive increase to of 277 percent from the previous 6 percent engagement rate.

InsuraGuest is positioned to tap into the opportunities presented by this fast-growing market by offering a product that fills an existing gap in travelers’ insurance. Conventional insurance fails to adequately cover the full scope of risks that travelers and hotel or property owners face. In cases where an incidence of damage or an accident cannot be attributed to the property directly, the guest may have no claim to coverage at all. Thus, InsuraGuest becomes the first line of defense for both the guest and the property, by providing specific coverage for issues such as accidental damage to rooms, lost or stolen items, medical expenses, and death or dismemberment.

Adoption of the technology is also made easy by the InsuraGuest™ InsurTech platform’s capability to integrate with more than 70 hotel and vacation rental property management systems worldwide. With that in mind, InsuraGuest is already working to expand the scope of its platform and products into the European Union, the United Kingdom, and Asia by the middle of next year.

Currently, the U.S. accounts for 20% of all vacation rental properties, Europe accounts for 60%, and the rest of the world accounts for 20%. Europe in general is an impressive hospitality stay market that’s twice the size of the U.S. market: according to InsuraGuest CEO Douglas Anderson, there were 2.8 billion hotel nights stayed in Europe, compared to approximately 1.1 billion in the U.S. in 2018.

InsuraGuest has already signed a letter of intent with a licensed Master General Agent operating in EU and U.K. markets, which will allow the company to distribute its products and proprietary platform to the hotel and vacation rental markets in these regions. Now offering coverage on the U.S. market coast-to-coast, expansion into Europe will also give InsuraGuest access to a combined demographic of 3.9 billion hotel nights stayed and significantly increase its opportunities for growth on the vacation rental markets in these regions.

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to InsuraGuest are available in the company’s newsroom at http://ibn.fm/InsuraGuest

• Most significant patent filed is also the most comprehensive, covering broad areas of cannabinoid polymeric nanoparticles and fibers
• Company is committed to continuing research program and expand its intellectual property portfolio over the coming months
• MCTC participating in multiple growing verticals within global cannabis industry through acquisitions, strategic partnerships, and intellectual property

MCTC Holdings Inc. (OTC: MCTC), a cannabinoid science innovator focused on high-growth and high-margins sub-sectors of the cannabis and hemp industry, filed its fourth cannabinoid delivery technology patent. The patent broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium, the company announced in a press release (http://ibn.fm/bCTyI).

MCTC’s R&D program continues with research into development of improved methods to give living systems access to cannabinoids. A key component of the research program is the development of novel polymeric nanofibers and nanoparticles, which have very high potential to significantly improve bioavailability, while allowing for tunability of cannabinoid combinations, ultra-high loading rates, precise dosing, and controlled release parameters at the same time.

According to CEO Arman Tabatabaei, this is the most significant patent the company has filed. “It is by far the most comprehensive covering broad areas of cannabinoid polymeric nanoparticles and fibers. The claims not only cover a plurality of particles within at least a partially water-soluble carrier, but also the process utilizing the precursor mixtures. Not only are nanoparticles and nanofibers included, but also particles below 1.5 microns,” Tabatabaei explained.

The company filed three other patents related to cannabinoid delivery systems in recent months. The first patent, which was on an edible dissolvable film for the delivery of cannabinoids, was the product of collaboration between MCTC and Cannabis Nanosciences, Inc. The companies also cooperated on the second patent, filed on cannabinoid nanoparticles combining TPGS, a water-soluble form of vitamin E. TPGS is a proven and safe bioenhancer of cannabinoids and other hydrophobic compounds. MCTC’s third patent was for a unique 3D printed, 4-dimensional, shape-changing cannabinoid delivery system for beverages.

“We expect to continue to expand our intellectual property portfolio over the coming weeks and months as our research and development programs continue. We believe the area of cannabinoid delivery systems is one of the most exciting areas of the growing cannabinoid sciences arena,” Tabatabaei added.

Currently pending a name change to Cannabis Global, Inc., MCTC Holdings is an integrated cannabis business operation focused on multiple verticals within the fast-growing cannabis and hemp industries via acquisitions, partnerships and intellectual property. An innovator in the field of cannabinoid nanoparticles and infusion technologies, the company concentrates its efforts on the middle part of the industry’s value chain, characterized by high margins and high growth. Its advanced cannabinoid delivery system research can revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and transdermal applications, with the potential for exponential growth in the industry.

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC